0.12(3.52%) Volume: 2,954,477 10:08PM EST| Market Cap : 1.84 B | Enterprise Value : 2.01 B | P/E (TTM) : | P/B : 1.03 |
|---|
OPK has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
OPK has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
GuruFocus Financial Strength Rank measures how strong a companys financial situation is. It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| vs
industry |
vs
history |
||
|---|---|---|---|
| Cash-to-Debt | 0.21 |
OPK's Cash-to-Debt is ranked lower than
74% of the 859 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 2.03 vs. OPK: 0.21 ) Ranked among companies with meaningful Cash-to-Debt only. |
OPK'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.13 Med: 6.97 Max: No Debt Current: 0.21 |
| Equity-to-Asset | 0.72 |
OPK's Equity-to-Asset is ranked higher than
65% of the 788 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 0.64 vs. OPK: 0.72 ) Ranked among companies with meaningful Equity-to-Asset only. |
OPK'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.41 Med: 0.7 Max: 0.96 Current: 0.72 |
| Debt-to-Equity | 0.12 |
OPK's Debt-to-Equity is ranked higher than
75% of the 596 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 0.32 vs. OPK: 0.12 ) Ranked among companies with meaningful Debt-to-Equity only. |
OPK'
s Debt-to-Equity Range Over the Past 10 Years
Min: -3.44 Med: 0.1 Max: 38.41 Current: 0.12 |
| Debt-to-EBITDA | -1.75 |
OPK's Debt-to-EBITDA is ranked lower than
99.99% of the 495 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 1.92 vs. OPK: -1.75 ) Ranked among companies with meaningful Debt-to-EBITDA only. |
OPK'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.03 Med: -0.92 Max: 3.46 Current: -1.75 |
| Piotroski F-Score: 1 |
|
| Altman Z-Score: 1.07 |
|
| Beneish M-Score: -3.37 |
|
| WACC vs ROIC |
1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank
| vs
industry |
vs
history |
||
|---|---|---|---|
| Operating Margin % | -24.62 |
OPK's Operating Margin % is ranked lower than
80% of the 801 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 7.97 vs. OPK: -24.62 ) Ranked among companies with meaningful Operating Margin % only. |
OPK'
s Operating Margin % Range Over the Past 10 Years
Min: -393.7 Med: -76.43 Max: -4.61 Current: -24.62 |
| Net Margin % | -28.96 |
OPK's Net Margin % is ranked lower than
79% of the 802 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 5.32 vs. OPK: -28.96 ) Ranked among companies with meaningful Net Margin % only. |
OPK'
s Net Margin % Range Over the Past 10 Years
Min: -421.97 Med: -64.09 Max: -2.05 Current: -28.96 |
| ROE % | -15.88 |
OPK's ROE % is ranked lower than
74% of the 832 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 5.94 vs. OPK: -15.88 ) Ranked among companies with meaningful ROE % only. |
OPK'
s ROE % Range Over the Past 10 Years
Min: -467.26 Med: -18.03 Max: -1.23 Current: -15.88 |
| ROA % | -11.57 |
OPK's ROA % is ranked lower than
73% of the 871 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 2.88 vs. OPK: -11.57 ) Ranked among companies with meaningful ROA % only. |
OPK'
s ROA % Range Over the Past 10 Years
Min: -129.9 Med: -12.23 Max: -0.83 Current: -11.57 |
| ROC (Joel Greenblatt) % | -140.53 |
OPK's ROC (Joel Greenblatt) % is ranked lower than
80% of the 855 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 11.23 vs. OPK: -140.53 ) Ranked among companies with meaningful ROC (Joel Greenblatt) % only. |
OPK'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -6953.23 Med: -169.39 Max: -43.73 Current: -140.53 |
| 3-Year Revenue Growth Rate | 106.80 |
OPK's 3-Year Revenue Growth Rate is ranked higher than
99% of the 689 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 5.80 vs. OPK: 106.80 ) Ranked among companies with meaningful 3-Year Revenue Growth Rate only. |
OPK'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0 Med: 27.65 Max: 152 Current: 106.8 |
| 3-Year EBITDA Growth Rate | 4.40 |
OPK's 3-Year EBITDA Growth Rate is ranked lower than
56% of the 704 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 7.30 vs. OPK: 4.40 ) Ranked among companies with meaningful 3-Year EBITDA Growth Rate only. |
OPK'
s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0 Med: -6.55 Max: 45.5 Current: 4.4 |
| 3-Year EPS without NRI Growth Rate | -10.30 |
OPK's 3-Year EPS without NRI Growth Rate is ranked lower than
76% of the 663 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 8.90 vs. OPK: -10.30 ) Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only. |
OPK'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -152.4 Med: 5.45 Max: 69.4 Current: -10.3 |
| Ken Fisher 36,379 sh (+12.35%) Murray Stahl 78,019 sh (+25.49%) | Jim Simons 159,991 sh (-85.15%) Mario Gabelli 86,800 sh (-8.20%) |
| Charles Brandes 664,840 sh (New) Murray Stahl 124,459 sh (+59.52%) Jim Simons 370,401 sh (+131.51%) Mario Gabelli 88,800 sh (+2.30%) | Ken Fisher Sold Out |
| Jim Simons Sold Out Charles Brandes 590,197 sh (-11.23%) Murray Stahl 92,897 sh (-25.36%) Mario Gabelli 77,800 sh (-12.39%) |
| Jim Simons 29,043 sh (New) Paul Tudor Jones 134,365 sh (New) | Mario Gabelli 77,800 sh (unchged) | Charles Brandes Sold Out Murray Stahl Sold Out |
(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
| Guru | Date | Action |
Impact | Price Range (Average)* |
Change from Average | Comment | Current Shares |
|---|
What is Peter Lynch Charts )| Industry: | Drug Manufacturers » Drug Manufacturers - Specialty & Generic NAICS: 325412 SIC: 2834 | |
|---|---|---|
| Compare: | NAS:PAHC, NAS:AKRX, SHSE:603567, HKSE:02877, TSE:8129, SZSE:300630, TSE:4555, NYSE:DPLO, XKRX:145020, NAS:MNTA, BOM:540596, BOM:532872, SHSE:600329, XKRX:041960, TSX:LEAF, SZSE:300401, SHSE:600781, BOM:533573, XKRX:003520, SZSE:002737 » details | |
| Traded in other countries: | XCY.Germany, OPK.Israel, OPK.Mexico, | |
| Headquarter Location: | USA |
| vs
industry |
vs
history |
||
|---|---|---|---|
| PB Ratio | 1.03 |
OPK's PB Ratio is ranked higher than
70% of the 819 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 2.64 vs. OPK: 1.03 ) Ranked among companies with meaningful PB Ratio only. |
OPK'
s PB Ratio Range Over the Past 10 Years
Min: 0.92 Med: 7.74 Max: 800 Current: 1.03 |
| PS Ratio | 1.79 |
OPK's PS Ratio is ranked higher than
50% of the 775 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 3.10 vs. OPK: 1.79 ) Ranked among companies with meaningful PS Ratio only. |
OPK'
s PS Ratio Range Over the Past 10 Years
Min: 1.59 Med: 30 Max: 158.13 Current: 1.79 |
| EV-to-EBIT | -8.97 |
OPK's EV-to-EBIT is ranked lower than
99.99% of the 572 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 17.85 vs. OPK: -8.97 ) Ranked among companies with meaningful EV-to-EBIT only. |
OPK'
s EV-to-EBIT Range Over the Past 10 Years
Min: -130.8 Med: -30.4 Max: 205.7 Current: -8.97 |
| EV-to-EBITDA | -16.79 |
OPK's EV-to-EBITDA is ranked lower than
99.99% of the 597 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 15.24 vs. OPK: -16.79 ) Ranked among companies with meaningful EV-to-EBITDA only. |
OPK'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -146.6 Med: -33.7 Max: 547.8 Current: -16.79 |
| EV-to-Revenue | 1.95 |
OPK's EV-to-Revenue is ranked higher than
50% of the 795 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 3.24 vs. OPK: 1.95 ) Ranked among companies with meaningful EV-to-Revenue only. |
OPK'
s EV-to-Revenue Range Over the Past 10 Years
Min: 1.7 Med: 30.9 Max: 161.4 Current: 1.95 |
| Current Ratio | 0.91 |
OPK's Current Ratio is ranked lower than
85% of the 855 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 2.39 vs. OPK: 0.91 ) Ranked among companies with meaningful Current Ratio only. |
OPK'
s Current Ratio Range Over the Past 10 Years
Min: 0.88 Med: 4.6 Max: 415 Current: 0.91 |
| Quick Ratio | 0.78 |
OPK's Quick Ratio is ranked lower than
79% of the 855 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 1.87 vs. OPK: 0.78 ) Ranked among companies with meaningful Quick Ratio only. |
OPK'
s Quick Ratio Range Over the Past 10 Years
Min: 0.48 Med: 4.09 Max: 415 Current: 0.78 |
| Days Inventory | 28.19 |
OPK's Days Inventory is ranked higher than
92% of the 755 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 119.80 vs. OPK: 28.19 ) Ranked among companies with meaningful Days Inventory only. |
OPK'
s Days Inventory Range Over the Past 10 Years
Min: 25.94 Med: 142.26 Max: 412.16 Current: 28.19 |
| Days Sales Outstanding | 55.72 |
OPK's Days Sales Outstanding is ranked higher than
72% of the 770 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 81.76 vs. OPK: 55.72 ) Ranked among companies with meaningful Days Sales Outstanding only. |
OPK'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.86 Med: 111.95 Max: 243.4 Current: 55.72 |
| Days Payable | 39.15 |
OPK's Days Payable is ranked lower than
78% of the 758 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 76.32 vs. OPK: 39.15 ) Ranked among companies with meaningful Days Payable only. |
OPK'
s Days Payable Range Over the Past 10 Years
Min: 31.85 Med: 101.87 Max: 193.93 Current: 39.15 |
| vs
industry |
vs
history |
||
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -9.00 |
OPK's 3-Year Average Share Buyback Ratio is ranked lower than
60% of the 571 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: -5.30 vs. OPK: -9.00 ) Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only. |
OPK'
s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -146.3 Med: -13.85 Max: 0.4 Current: -9 |
| vs
industry |
vs
history |
||
|---|---|---|---|
| Price-to-Intrinsic-Value-Projected-FCF | 2.23 | ||
| Price-to-Median-PS-Value | 0.06 |
OPK's Price-to-Median-PS-Value is ranked higher than
99% of the 743 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 0.94 vs. OPK: 0.06 ) Ranked among companies with meaningful Price-to-Median-PS-Value only. |
OPK'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.06 Med: 1.33 Max: 30 Current: 0.06 |
| Earnings Yield (Greenblatt) % | -11.15 |
OPK's Earnings Yield (Greenblatt) % is ranked lower than
81% of the 867 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 3.31 vs. OPK: -11.15 ) Ranked among companies with meaningful Earnings Yield (Greenblatt) % only. |
OPK'
s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -25.6 Med: -3.1 Max: 0.5 Current: -11.15 |
| Revenue (TTM) (Mil) $ | 1,030.90 |
|---|---|
| EPS (TTM) $ | -0.53 |
| Beta | 1.66 |
| Volatility | 67.84% |
| 52-Week Range $ | 2.66 - 6.40 |
| Shares Outstanding (Mil) | 586.33 |
| Dec18 | Dec19 | Dec20 | Dec21 | |
|---|---|---|---|---|
| Revenue (Mil $) | 1,008 | 1,041 | 1,157 | 1,374 |
| EBIT (Mil $) | ||||
| EBITDA (Mil $) | ||||
| EPS ($) | -0.20 | -0.17 | -0.02 | 0.11 |
| EPS without NRI ($) | -0.20 | -0.17 | -0.02 | 0.11 |
| EPS Growth Rate (Future 3Y To 5Y Estimate) | 12.00% | |||
| Dividends per Share ($) | ||||
|
GF Chat
Excel Add-In GURUF
API
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
My Gurus
Email Alerts
Stock PDF
RSS
Website
Filings
Manual of Stocks™ Web APP